- Home
- BLFS vs JANX Comparison
BLFS vs JANX Comparison
Compare BLFS & JANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | BLFS | JANX |
|---|---|---|
| Founded | 1987 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 923.5M | 790.3M |
| IPO Year | 2013 | 2021 |
Fundamental Metrics
Financial Performance| Metric | BLFS | JANX |
|---|---|---|
| Price | $18.59 | $13.19 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 11 |
| Target Price | $32.00 | ★ $53.60 |
| AVG Volume (30 Days) | 494.2K | ★ 834.3K |
| Earning Date | 05-07-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 77.27 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $96,214,000.00 | $10,000,000.00 |
| Revenue This Year | $19.73 | N/A |
| Revenue Next Year | $17.82 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 16.97 | N/A |
| 52 Week Low | $17.86 | $12.12 |
| 52 Week High | $29.57 | $35.34 |
Technical Indicators
Market Signals| Indicator | BLFS | JANX |
|---|---|---|
| Relative Strength Index (RSI) | 37.55 | 41.58 |
| Support Level | $17.86 | $13.12 |
| Resistance Level | $26.77 | $13.79 |
| Average True Range (ATR) | 0.84 | 0.51 |
| MACD | 0.12 | -0.05 |
| Stochastic Oscillator | 25.10 | 2.04 |
Price Performance
Historical ComparisonAbout BLFS BioLife Solutions Inc.
BioLife Solutions Inc is a life sciences company that develops, manufactures, and markets bioproduction products and services that are designed to improve quality and de-risk biologic manufacturing, distribution, and transportation in the cell and gene therapy ("CGT") industry. The company provides solutions such as Cell Processing, Cold Chain, and Thawing. The company generates the majority of its revenue from Cell Processing through the biopreservation product "CryoStor". Geographically the company generates the majority of its revenue from the United States.
About JANX Janux Therapeutics Inc.
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. Its proprietary technology has enabled the development of two distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr). The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain.